Legend Biotech Past Earnings Performance
Past criteria checks 0/6
Legend Biotech's earnings have been declining at an average annual rate of -15.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 47.7% per year.
Key information
-15.5%
Earnings growth rate
-4.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 47.7% |
| Return on equity | -31.2% |
| Net Margin | -66.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Legend Biotech: The Story Brightens
Dec 05Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking
Aug 01Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt
Jul 05Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio
May 13Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07Legend Biotech: Carvykti Approval Makes For A Buy Opportunity
Mar 04Revenue & Expenses Breakdown
How Legend Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 520 | -348 | 264 | 0 |
| 30 Jun 24 | 456 | -285 | 233 | 0 |
| 31 Mar 24 | 343 | -466 | 217 | 0 |
| 31 Dec 23 | 285 | -518 | 201 | 0 |
| 30 Sep 23 | 233 | -509 | 191 | 0 |
| 30 Jun 23 | 165 | -532 | 184 | 0 |
| 31 Mar 23 | 112 | -517 | 180 | 0 |
| 31 Dec 22 | 117 | -446 | 174 | 0 |
| 30 Sep 22 | 106 | -416 | 192 | -227 |
| 30 Jun 22 | 96 | -457 | 181 | -155 |
| 31 Mar 22 | 119 | -346 | 161 | 313 |
| 31 Dec 21 | 69 | -404 | 150 | 0 |
| 30 Sep 21 | 93 | -356 | 113 | 294 |
| 30 Jun 21 | 89 | -297 | 97 | 285 |
| 31 Mar 21 | 80 | -340 | 85 | 184 |
| 31 Dec 20 | 75 | -266 | 73 | 0 |
| 30 Sep 20 | 59 | -310 | 55 | 231 |
| 30 Jun 20 | 64 | -271 | 46 | 210 |
| 31 Mar 20 | 61 | -165 | 38 | 189 |
| 01 Jan 20 | 62 | -102 | 32 | 162 |
| 31 Dec 18 | 49 | -3 | 4 | 61 |
| 31 Dec 17 | 24 | 9 | 2 | 8 |
Quality Earnings: LEGN is currently unprofitable.
Growing Profit Margin: LEGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LEGN is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare LEGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LEGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LEGN has a negative Return on Equity (-31.19%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Legend Biotech Corporation is covered by 27 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |